annb0t
Top 20
MELBOURNE, Australia, April 6, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) welcomes the listing of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) (PSMA-PET) imaging for patients with prostate cancer on the Medicare Benefits Schedule (MBS) from 1 July 2022. (PRNewsfoto/Telix Pharmaceuticals Limited)
MBS funding will cover the initial staging of intermediate to high-risk patients with prostate cancer and the restaging of patients...
>>> Read more: PSMA-PET Imaging to be Funded through Medicare in Australia from July 2022
MBS funding will cover the initial staging of intermediate to high-risk patients with prostate cancer and the restaging of patients...
>>> Read more: PSMA-PET Imaging to be Funded through Medicare in Australia from July 2022
